Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • Nelarabine Injection
  • Pipeline
    • SH-105
    • SH-110
    • SH-114
  • News
    • Company Updates
    • Media
  • Contact

News

Shorla Oncology at BioEquity Europe 2023 in Dublin

May 16th 2023

Read More

Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection

May 16th 2023

Read More

Step Challenge for Oscars Kids!

April 25th 2023

Read More

Shorla Oncology will be attending Asembia’s ASX Summit in Las Vegas

April 17th 2023

Read More

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 27th 2023

Read More

Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023

March 23rd 2023

Read More

US FDA approves Shorla’s oncology drug for T-cell leukaemia

March 20th 2023

Read More

Shorla wins FDA approval for leukaemia drug

March 20th 2023

Read More

Irish-founded Shorla Oncology secures FDA approval for leukaemia drug

March 9th 2023

Read More

Older posts
Page1 Page2 … Page10

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

 

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2022

© 2023 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • Nelarabine Injection
  • Pipeline
    • SH-105
    • SH-110
    • SH-114
  • News
    • Company Updates
    • Media
  • Contact